Abstract A study by Chan et al in this issue of Diabetologia
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In this issue of Diabetologia, Chan et al [1] report the results of a pre-specified subsidiary analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. This trial included 9,795 patients with type 2 diabetes mellitus. Lower bilirubin levels increased the risk of first amputation (HR 1.38 per 5 μmol/l decrease in bilirubin concentration; 95% CI 1.05, 1.81; p=0.019) after multiple adjustments. These adjustments included age, height, smoking status, γ-glutamyltransferase activity, HbA 1c level and trial treatment allocation (placebo vs fenofibrate), as well as previous peripheral artery disease (PAD), non-PAD cardiovascular disease, amputation or diabetic skin ulcer, neuropathy, nephropathy and diabetic retinopathy. The authors conclude that their findings raise the hypothesis that bilirubin protects against the need for amputation in patients with type 2 diabetes. The hypothesis for this subsidiary analysis was that several actions attributed to bilirubin that may protect from atherosclerosis (e.g. antioxidant and anti-inflammatory effects) [1, 2] might also extend to decreasing the risk of amputation in patients with type 2 diabetes. These findings are not only of interest in terms of explaining the pathogenesis leading to amputation but also in pointing towards future treatment options. There is also a need for useful biomarkers that both predict the risk of amputation and alter outcomes. This would not only improve quality of life but also reduce the considerable cost associated with amputation, especially in patients at high risk of needing this procedure (e.g. those with type 2 diabetes) [1] .
The authors discuss several limitations of their study [1] . There were only 190 amputations (115 patients) over the 5 year duration of the FIELD trial [1] . This limits the power of multiple adjustments in specific patient subgroups. Some of these limitations need to be viewed in the context of variables that can influence bilirubin levels. For example, women and smokers have lower bilirubin levels than men and non-smokers, respectively, as was appreciated by the authors [1] . In turn, smokers had a greater risk of amputation than non-smokers, and women had a lower risk than men [1] . Furthermore, there is also an effect of glycaemia on bilirubin levels [1] ; for example, others have reported that higher HbA 1c levels were associated with lower bilirubin levels in patients with type 2 diabetes [3] . This association is of interest because the amputation group had higher HbA 1c levels than those who did not need an amputation during the FIELD trial [1] . The amputation group also had a higher mean plasma creatinine level [1] . In this context, we need to consider that fenofibrate can raise plasma creatinine levels [4] and that this fibrate reduced the amputation rate in the FIELD trial (HR 0.64, 95% CI 0.44, 0.94 after adjusting for bilirubin; p=0.02) [1] .
All the patients in the FIELD trial had type 2 diabetes; therefore, it is of interest that a high total bilirubin level may protect against diabetes (an effect possibly related to actions of bilirubin on glucose metabolism, among other mechanisms) [5] [6] [7] . This protection may extend to diabetic nephropathy [6] and retinopathy [8] , although the literature is not consistent. Does this mean that, in terms of bilirubin levels, there was an element of unintentional pre-selection in the FIELD trial?
Whatever the limitations of this pre-specified subsidiary analysis of the FIELD study, it is relevant that others have reported a similar link between amputation risk and bilirubin levels in different populations [1] .
The use of statins was associated with lower bilirubin levels in one study that included patients at high cardiovascular risk (diabetes, hypercholesterolaemia or vascular disease) [9] . We have shown, in a small study, that bilirubin levels were lower in untreated hypertensive individuals compared with normotensive people or treated hypertensive patients. We attributed this effect to the antioxidant actions of certain drugs used to treat hypertension and to a higher level of oxidative stress in untreated hypertensive patients [10] . These studies suggest that commonly used drug treatments (i.e. for dyslipidaemia and hypertension) may influence bilirubin levels. Lower serum bilirubin levels were also reported in patients with the metabolic syndrome, in which bilirubin negatively correlated with circulating insulin levels and visceral adipose tissue [11] . In a large prospective study (5,900 Korean men; followed up between 2002 and 2009) higher serum direct (conjugated) bilirubin levels were significantly associated with a lower risk of developing nonalcoholic fatty liver disease (NAFLD) [12] . Less than 1% of the participants in the study had diabetes. One of the limitations of this study [12] is that the diagnosis of NAFLD was based on ultrasound findings instead of the 'gold standard' liver biopsy. However, it is difficult to see how such a large study could cope with the logistics of liver biopsies let alone the ethical restrictions associated with such a procedure. The relevance of these findings is that NAFLD is both common in patients with type 2 diabetes and has been proposed as a predictor of increased vascular risk [13, 14] . However, we were unable to find any literature on NAFLD and risk of amputation. We therefore need to consider whether such effects are relevant to the design of future studies aimed at defining any link between vascular pathology and circulating bilirubin levels.
Despite limitations, the findings of this FIELD prespecified subsidiary analysis [1] are of interest as they extend our knowledge of the link between bilirubin and vascular disease. However, because of the variability in the evidence regarding the role of bilirubin in vascular disease [1, 2] , more research is urgently needed in this field. One rapid way of dealing with this problem is to analyse the role of bilirubin in published trials where this information is available [2] . This is a credible option since bilirubin levels may predict risk even in patients taking statins [15] . It goes without saying that future designs of vascular trials should incorporate an analysis of the role of bilirubin.
There may be several reasons for the lack of agreement in the literature regarding how bilirubin might influence vascular pathology. Among these is that different populations (even within a single study) were sampled, and the fact that there are numerous relationships between bilirubin levels and other predictors of vascular risk (including NAFLD, sex and smoking status, as well as fasting insulin, triacylglycerol, HbA 1c and exercise levels) [1, 2, 16, 17] . Furthermore, bilirubin may reflect other changes that are relevant to vascular risk [2, 18] . Undoubtedly it is difficult to adjust correctly for all these variables and thus defining the exact role of bilirubin in terms of vascular risk remains elusive.
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